Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zurlectrectinib
- Development stage
- Phase 2
- Lead developer
- InnoCare Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Zurlectrectinib is a highly selective, next-generation small molecule tyrosine kinase inhibitor developed by InnoCare Pharma. It targets neurotrophic tyrosine receptor kinase (TRK) fusions (NTRK1, NTRK2, and NTRK3) and is indicated for the treatment of NTRK fusion-positive solid tumors. The drug has demonstrated encouraging efficacy and manageable toxicity in clinical trials, including in patients with brain metastasis and those resistant to first-generation TRK inhibitors, due to its strong brain penetration and intracranial activity.
- Brand names
- zurletrectinib
- Other names
- ICP-723ICP723ICP 723zurletrectinib
02
Targets
NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on zurlectrectinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zurlectrectinib.